Fate Therapeutics Inc
Fate Therapeutics Inc
FATE

Fate Therapeutics Inc (FATE)

$24.780.4%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$23.54
Day's Range
$25.0
$17.1
52-Week Range
$97.43
1 month return7.71%
3 month return39.79%
1 year return71.53%
5 year return779.15%

Company Information

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company's immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. Fate Therapeutics is headquartered in San Diego, CA.
OrganizationFate Therapeutics Inc
Employees279
CEOWilliam Rastetter
IndustryHealth Technology

Analyst Recommendation

based on 26 analysts ratings

Buy
80%
Buy
19%
Hold
0%
Sell

Based on 26 Wall street analysts offering stock ratings for Fate Therapeutics Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 259.6%

Current

$24.78

Target

$89.11

Recommendation Trend

Based on 26 analyst

Current1M Ago3M Ago
Buy
21
21
20
Hold
5
5
5
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
3.1B
Book Value
7.09
Dividend Share
0.0
Dividend Yield
0.0
Earnings Share
-2.24
PEG Ratio
0.0
Wall Street Target Price
91.89

Valuation

Trailing PE0.0
Forward PE0.0
Price/Sales (ttm)
55.12
Price/Book (mrq)
4.92
Enterprise Value
2.8B
Enterprise Value/Revenue
50.82
Enterprise Value/Ebitda
0.0

Technicals

Beta
1.56
50 Day MA
35.98
200 Day MA
55.06

Institutional Holdings

Redmile Group, LLC

13.41%

ARK Investment Management LLC

11.37%

Vanguard Group Inc

7.96%

BlackRock Inc

7.31%

T. Rowe Price Associates, Inc.

5.08%

Capital World Investors

4.72%

Discover more

Frequently Asked Questions

What is Fate Therapeutics Inc share price today?

Can Indians buy Fate Therapeutics Inc shares?

How can I buy Fate Therapeutics Inc shares from India?

Can Fractional shares of Fate Therapeutics Inc be purchased?

What are the documents required to start investing in Fate Therapeutics Inc stocks?

What are today’s High and Low prices of Fate Therapeutics Inc?

What are today’s traded volumes of Fate Therapeutics Inc?

What is today’s market capitalisation of Fate Therapeutics Inc?

What is the 52 Week High and Low Range of Fate Therapeutics Inc?

How much percentage Fate Therapeutics Inc is down from its 52 Week High?

How much percentage Fate Therapeutics Inc is up from its 52 Week low?

What are the historical returns of Fate Therapeutics Inc?

Who is the Chief Executive Officer (CEO) of Fate Therapeutics Inc?